PL400151A1 - Kompozycja dietetyczna do redukcji masy ciala oraz zastosowanie aminokwasów egzogennych do wytwarzania kompozycji dietetycznej - Google Patents
Kompozycja dietetyczna do redukcji masy ciala oraz zastosowanie aminokwasów egzogennych do wytwarzania kompozycji dietetycznejInfo
- Publication number
- PL400151A1 PL400151A1 PL400151A PL40015112A PL400151A1 PL 400151 A1 PL400151 A1 PL 400151A1 PL 400151 A PL400151 A PL 400151A PL 40015112 A PL40015112 A PL 40015112A PL 400151 A1 PL400151 A1 PL 400151A1
- Authority
- PL
- Poland
- Prior art keywords
- dietary composition
- amino acids
- make
- body weight
- exogenous amino
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title abstract 4
- 235000007882 dietary composition Nutrition 0.000 title abstract 4
- 230000037396 body weight Effects 0.000 title 1
- 229940024606 amino acid Drugs 0.000 abstract 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 239000013585 weight reducing agent Substances 0.000 abstract 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Kompozycja dietetyczna do redukcji masy ciala, charakteryzuje sie tym, ze bialko zastapione jest aminokwasami, które stanowia aminokwasy egzogenne w postaci wolnej, wybrane sposród leucyny od 6,83 do 9,75%, lizyny od 5,25% do 7,50%, waliny od 4,55% do 6,50%, fenyloalaniny od 4,38% do 6,25%, izoleucyny od 3,5% do 5%, metioniny od 2,63% do 3,75%, treoniny od 2,63% do 3,75% i tryptofanu od 0,7% do 1%. Wynalazek dotyczy równiez zastosowania aminokwasów egzogennych w postaci wolnej do wytwarzania tej kompozycji dietetycznej.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL400151A PL400151A1 (pl) | 2012-07-27 | 2012-07-27 | Kompozycja dietetyczna do redukcji masy ciala oraz zastosowanie aminokwasów egzogennych do wytwarzania kompozycji dietetycznej |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL400151A PL400151A1 (pl) | 2012-07-27 | 2012-07-27 | Kompozycja dietetyczna do redukcji masy ciala oraz zastosowanie aminokwasów egzogennych do wytwarzania kompozycji dietetycznej |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL400151A1 true PL400151A1 (pl) | 2014-02-03 |
Family
ID=50023108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL400151A PL400151A1 (pl) | 2012-07-27 | 2012-07-27 | Kompozycja dietetyczna do redukcji masy ciala oraz zastosowanie aminokwasów egzogennych do wytwarzania kompozycji dietetycznej |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL400151A1 (pl) |
-
2012
- 2012-07-27 PL PL400151A patent/PL400151A1/pl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| PH12012501842B1 (en) | Low protein infant formula with increased essential amino acids | |
| BR112013031268A8 (pt) | polipeptídeos | |
| EA201790378A1 (ru) | Заключенное в липосому аффинное лекарственное средство | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| PH12013502027B1 (en) | Nutritional compositions having alpha-hica and alpha-ketoglutarate | |
| MX2021001169A (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. | |
| MX2016010951A (es) | Proteinas de fc multimericas. | |
| MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| MX342257B (es) | Derivados y análogos de oxaspiro [2.5] octano. | |
| MY161390A (en) | Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations | |
| MY182593A (en) | Composition containing chitin and digestible proteins | |
| MX2021006945A (es) | Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas. | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| PH12017500481A1 (en) | Novel soluble guanylate cyclase activators and their use | |
| PH12014502352A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
| BR112015031417A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| PH12014501200B1 (en) | Bacteriophage gene 3 protein compositions and use as amyloid binding agents | |
| PH12015501870B1 (en) | Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof | |
| CO2017001601A2 (es) | Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio | |
| BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
| MX2016016491A (es) | Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas. | |
| UY33663A (es) | Derivados amínicos para el tratamiento de trastornos proliferativos de la piel | |
| PH12013502643A1 (en) | Improved food composition | |
| EA201300947A1 (ru) | Композиция для повышения устойчивости суставов и/или позной устойчивости |